Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
221 Crescent St., Building 17, Suite 102 B, Waltham, MA
Fiscal year end
December 31
Former names
Apogee Therapeutics, LLC (to 6/12/2023)
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.39K %
Return On Assets -23.1 %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 58.1M shares +20.1%
Entity Public Float 1.43B USD
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 55.2M shares +121%
Weighted Average Number of Shares Outstanding, Diluted 55.2M shares +121%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 168M USD +145%
General and Administrative Expense 49M USD +99.4%
Operating Income (Loss) -217M USD -133%
Net Income (Loss) Attributable to Parent -182M USD -117%
Earnings Per Share, Basic -3.3 USD/shares +1.79%
Earnings Per Share, Diluted -3.3 USD/shares +1.79%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142M USD +19.8%
Marketable Securities, Current 379M USD +36.7%
Other Assets, Current 1.74M USD +43.5%
Assets, Current 530M USD +33%
Property, Plant and Equipment, Net 1.96M USD +420%
Operating Lease, Right-of-Use Asset 11.4M USD +413%
Other Assets, Noncurrent 498K USD +24.2%
Assets 754M USD +87.8%
Accounts Payable, Current 1.07M USD -50%
Employee-related Liabilities, Current 1.9M USD +1035%
Accrued Liabilities, Current 24.3M USD +40.1%
Liabilities, Current 28.6M USD +38.9%
Operating Lease, Liability, Noncurrent 8.6M USD +821%
Liabilities 37.2M USD +72.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 915K USD +178%
Retained Earnings (Accumulated Deficit) -306M USD -147%
Liabilities and Equity 754M USD +87.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.6M USD -200%
Net Cash Provided by (Used in) Financing Activities 451M USD
Net Cash Provided by (Used in) Investing Activities -51.7M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 59.5M shares +17.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 367M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 142M USD +19.8%
Deferred Tax Assets, Valuation Allowance 76.1M USD +152%
Deferred Tax Assets, Gross 78.8M USD +156%
Operating Lease, Liability 11.8M USD +492%
Depreciation 29K USD
Payments to Acquire Property, Plant, and Equipment 351K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -182M USD -117%
Lessee, Operating Lease, Liability, to be Paid 13.2M USD +496%
Operating Lease, Liability, Current 3.23M USD +194%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.48M USD +260%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.91M USD +214%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -30%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.33M USD +664%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.05M USD
Deferred Tax Assets, Operating Loss Carryforwards 16.1M USD +200%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 3.6M USD +299%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.11M USD
Additional Paid in Capital 1.02B USD +103%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 23.3M USD +282%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares